185 related articles for article (PubMed ID: 33446046)
1. Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
Chang ML; Lin YS; Chang MY; Hsu CL; Chien RN; Fann CS
Virulence; 2021 Dec; 12(1):270-280. PubMed ID: 33446046
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
3. Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity.
Chang ML; Kuo CJ; Huang HC; Chu YY; Chiu CT
PLoS One; 2016; 11(11):e0166712. PubMed ID: 27870883
[TBL] [Abstract][Full Text] [Related]
4. Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus.
Wong GL; Chan HL; Tse CH; Chan PO; Cheng JC; Cheng JS; Lau SH; Lee EK; Ma JM; Chan AW; Choi PC; Wong VW
J Gastroenterol Hepatol; 2015 Jun; 30(6):1040-8. PubMed ID: 25639146
[TBL] [Abstract][Full Text] [Related]
5. The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance.
Chang ML; Kuo CJ; Pao LH; Hsu CM; Chiu CT
Virulence; 2017 Oct; 8(7):1255-1264. PubMed ID: 28267407
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Nicotinamide Phosphoribosyltransferase as a Surrogate Marker of Prominent Malignant Potential in Colonic Polyps: A 2-Year Prospective Study.
Chen TH; Hsu HC; You JF; Lai CC; Tsou YK; Hsu CL; Fann CSJ; Chien RN; Chang ML
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980589
[TBL] [Abstract][Full Text] [Related]
7. Association of Nicotinamide Phosphoribosyltransferase (NAMPT) Gene Polymorphisms and of Serum NAMPT Levels with Dilated Cardiomyopathy in a Chinese Population.
Dou Q; Peng Y; Zhou B; Zhang K; Lin J; Dai X; Zhang L; Rao L
Int J Mol Sci; 2015 Sep; 16(9):22299-318. PubMed ID: 26389889
[TBL] [Abstract][Full Text] [Related]
8. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.
Lee H; Chien RN; Pao LH; Kuo CJ; Huang PH; Chang ML
Cells; 2021 Oct; 10(11):. PubMed ID: 34831156
[TBL] [Abstract][Full Text] [Related]
9. Correlation between polymorphisms in the visfatin gene and its expression in the serum and coronary artery calcification.
Jin LW; Zheng SB; Zhou ZH; Pan SF; Zheng Y
Genet Mol Res; 2016 Jul; 15(2):. PubMed ID: 27421003
[TBL] [Abstract][Full Text] [Related]
10. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.
Shimada N; Toyoda H; Tsubota A; Ide T; Takaguchi K; Kato K; Kondoh M; Matsuyama K; Kumada T; Sata M
J Gastroenterol; 2014 Nov; 49(11):1485-94. PubMed ID: 24287582
[TBL] [Abstract][Full Text] [Related]
11. Linkage of NAMPT promoter variants to eNAMPT secretion, plasma eNAMPT levels, and ARDS severity.
Lynn H; Sun X; Casanova NG; Bime C; Reyes Hernon V; Lanham C; Oita RC; Ramos N; Sun B; Coletta DK; Camp SM; Karnes JH; Ellis NA; Garcia JGN
Ther Adv Respir Dis; 2023; 17():17534666231181262. PubMed ID: 37477094
[TBL] [Abstract][Full Text] [Related]
12. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
Wu R; Chi X; Wang X; Sun H; Lv J; Gao X; Yu G; Kong F; Xu H; Hua R; Jiang J; Sun B; Zhong J; Pan Y; Niu J
Infect Genet Evol; 2016 Apr; 39():132-140. PubMed ID: 26820907
[TBL] [Abstract][Full Text] [Related]
13. The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
Belo VA; Luizon MR; Lacchini R; Miranda JA; Lanna CM; Souza-Costa DC; Tanus-Santos JE
Int J Obes (Lond); 2015 Jan; 39(1):130-5. PubMed ID: 24100423
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
[TBL] [Abstract][Full Text] [Related]
15. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
16. Recovery of lipid metabolic alterations in hepatitis C patients after viral clearance: Incomplete restoration with accelerated ω-oxidation.
Chang SW; Cheng ML; Shiao MS; Yeh CT; Wang CH; Fan CM; Chiu CT; Chang ML
J Clin Lipidol; 2018; 12(3):756-766. PubMed ID: 29574072
[TBL] [Abstract][Full Text] [Related]
17. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
18. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
Thong VD; Wasitthankasem R; Tangkijvanich P; Vongpunsawad S; Poovorawan Y
PLoS One; 2015; 10(5):e0125400. PubMed ID: 25938236
[TBL] [Abstract][Full Text] [Related]
20. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
